Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

ABSTRACT Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic Myeloid Leukemia. This study aimed to ev...

Full description

Bibliographic Details
Main Authors:	Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres
Format:	Article
Language:	English
Published:	Universidade de São Paulo
Series:	Brazilian Journal of Pharmaceutical Sciences
Subjects:	Chronic Myeloid Leukemia/treatment Imatinib Mesylate/treatment adherence Medication adherence Pharmacotheraphy review.
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502016000400581&lng=en&tlng=en

Similar Items

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Renal phosphate loss in Iraqi chronic myeloid leukemia patients treated by imatinib mesylate
by: Huda A Al-Taee, et al.
Published: (2020-01-01)

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Chronic subdural hematoma-unsual cause of headache in a patient with chronic myeloid leukemia treated with high-dose imatinib mesylate: A rare case report with review of literature
by: Sanjay M Khaladkar, et al.
Published: (2015-01-01)

OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01)

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy
by: Ćojbašić Irena, et al.
Published: (2010-01-01)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011-06-01)

THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

The efficacy of generic imatinib in patients with chronic myeloid leukemia: A single centre experience
by: Urošević Ivana, et al.
Published: (2021-01-01)

Lack of Association of Multidrug Resistance Gene-1 Polymorphisms with Treatment Outcome in Chronic Myeloid Leukemia Patients Treated with Imatinib
by: Yaya Kassogue, et al.
Published: (2015-10-01)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
by: Asiyeh Amouei, et al.
Published: (2021-04-01)

FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY
by: Jyotsna Kapoor, et al.
Published: (2015-02-01)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
by: Marjanu Hikmah Elias, et al.
Published: (2012-11-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases Tratamento da leucemia mielóide crônica com imatinib mesilato no Brasil: estudo de 98 casos
by: Vaneuza A. M. Funke, et al.
Published: (2005-09-01)

Chronic Myeloid Leukemia with Variant Chromosomal Translocations: Results of Treatment with Imatinib Mesylate
by: Rohan Bhise, et al.
Published: (2013-01-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line
by: Corrêa Stephany, et al.
Published: (2012-03-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Comparison of effectiveness and safety of Iranian-made vs. Indian-made imatinib in treatment of chronic myeloid leukemia
by: Kamran Moshfeghi, et al.
Published: (2013-01-01)

Monitoring of Disease Activity in Chronic Myeloid Leukemia-chronic Phase Patients Treated with Indian Generic Veenat (NATCO) Imatinib Mesylate: A Tertiary Care Experience
by: Khushboo Dewan, et al.
Published: (2015-01-01)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
by: Ana Lucia Vieira-Mion, et al.

Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience
by: Wael Abdelgawad Edesa, et al.
Published: (2015-06-01)

Prognosic Factors Related to The Complete Hematologic Response (CHR) in 3 Months in Leukemia Granulositic Patients Administered with Imatinib Mesylate
by: Ikhwan Rinaldi, et al.
Published: (2020-09-01)

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
by: Malkan Umit Y., et al.
Published: (2018-12-01)

Tratamento da recidiva da leucemia mielóide crônica após transplante de medula óssea alogênico utilizando mesilato de imatinibe: relato de três casos Treatment of chronic myelogenous leukemia relapse after allogeneic bone marrow transplantation with imatinib mesylate: report of three cases
by: Ronald Pallotta, et al.
Published: (2006-06-01)

Aplasia irreversible por el tratamiento con mesilato de Imatinib en una leucemia mieloide crónica: Presentación de un caso Irreversible aplasia due to the treatment with imatinib mesilate in a chronic myeloid leukemia: A case report
by: Olga Agramonte Llanes, et al.
Published: (2007-04-01)

Leucemia Mielóide Crônica em pediatria: perspectivas atuais Chronic Myeloid Leukemia in pediatrics patients: current approach
by: Maria Lucia M. Lee
Published: (2008-04-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)